Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491550 | ||
| 003 | CHVBK | ||
| 005 | 20210128100510.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151001xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-015-0802-y |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-015-0802-y | ||
| 245 | 0 | 0 | |a Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis |h [Elektronische Daten] |c [Takuya Koie, Koji Mitsuzuka, Takahiro Yoneyama, Shintaro Narita, Sadafumi Kawamura, Yasuhiro Kaiho, Norihiko Tsuchiya, Tatsuo Tochigi, Tomonori Habuchi, Yoichi Arai, Chikara Ohyama, Tohru Yoneyama, Yuki Tobisawa] |
| 520 | 3 | |a Background: The optimal treatment for high-risk prostate cancer (Pca) remains to be established. We previously reported favorable biochemical recurrence-free survival (BRFS) in high-risk Pca patients treated with a neoadjuvant therapy comprising a luteinizing-hormone-releasing hormone (LHRH) agonist plus low dose estramustine phosphate (EMP) (LHRH+EMP) followed by radical prostatectomy (RP). In the present study, we used a retrospective design via propensity score matching to elucidate the clinical benefit of neoadjuvant LHRH+EMP for high-risk Pca. Methods: The Michinoku Urological Cancer Study Group database contained data for 1,268 consecutive Pca patients treated with RP alone at 4 institutions between April 2000 and March 2011 (RP alone group). In the RP alone group, we identified 386 high-risk Pca patients. The neoadjuvant LHRH+EMP group included 274 patients with high-risk Pca treated between September 2005 and November 2013 at Hirosaki University. Neoadjuvant LHRH+EMP therapy included LHRH and EMP administration at a dose of 280mg/day for 6months before RP. The outcome measures were overall survival (OS) and BRFS. Results: The propensity score-matched analysis indicated 210 matched pairs from both groups. The 5-year BRFS rates were 90.4 and 65.8% for the neoadjuvant LHRH+EMP and RP alone groups, respectively (P<0.0001). The 5-year OS rates were 100 and 96.1% for the neoadjuvant LHRH+EMP and RP alone groups, respectively (P=0.110). Conclusions: Although the present study was not randomized, neoadjuvant LHRH+EMP therapy followed by RP appeared to reduce the risk of biochemical recurrence. A prospective randomized study is warranted to determine the clinical implications of the neoadjuvant therapy described here. | |
| 540 | |a Japan Society of Clinical Oncology, 2015 | ||
| 690 | 7 | |a High-risk prostate cancer |2 nationallicence | |
| 690 | 7 | |a Prostatectomy |2 nationallicence | |
| 690 | 7 | |a Neoadjuvant therapy |2 nationallicence | |
| 690 | 7 | |a LHRH plus estramustine |2 nationallicence | |
| 690 | 7 | |a Propensity score analysis |2 nationallicence | |
| 700 | 1 | |a Koie |D Takuya |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | |
| 700 | 1 | |a Mitsuzuka |D Koji |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | |
| 700 | 1 | |a Yoneyama |D Takahiro |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | |
| 700 | 1 | |a Narita |D Shintaro |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | |
| 700 | 1 | |a Kawamura |D Sadafumi |u Department of Urology, Miyagi Cancer Center, Natori, Japan |4 aut | |
| 700 | 1 | |a Kaiho |D Yasuhiro |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | |
| 700 | 1 | |a Tsuchiya |D Norihiko |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | |
| 700 | 1 | |a Tochigi |D Tatsuo |u Department of Urology, Miyagi Cancer Center, Natori, Japan |4 aut | |
| 700 | 1 | |a Habuchi |D Tomonori |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | |
| 700 | 1 | |a Arai |D Yoichi |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | |
| 700 | 1 | |a Ohyama |D Chikara |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | |
| 700 | 1 | |a Yoneyama |D Tohru |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | |
| 700 | 1 | |a Tobisawa |D Yuki |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/5(2015-10-01), 1018-1025 |x 1341-9625 |q 20:5<1018 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-015-0802-y |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-015-0802-y |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Koie |D Takuya |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Mitsuzuka |D Koji |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yoneyama |D Takahiro |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Narita |D Shintaro |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kawamura |D Sadafumi |u Department of Urology, Miyagi Cancer Center, Natori, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kaiho |D Yasuhiro |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tsuchiya |D Norihiko |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tochigi |D Tatsuo |u Department of Urology, Miyagi Cancer Center, Natori, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Habuchi |D Tomonori |u Department of Urology, Akita University Graduate School of Medicine, Akita, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Arai |D Yoichi |u Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ohyama |D Chikara |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yoneyama |D Tohru |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Tobisawa |D Yuki |u Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, 036-8562, Hirosaki, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/5(2015-10-01), 1018-1025 |x 1341-9625 |q 20:5<1018 |1 2015 |2 20 |o 10147 | ||